- Home
- / Gritstone bio
Gritstone bio
Stock Price
$0
2024-10-29
Market Capitalization
$3.8 M
2024-10-29
Revenue
$16.3 M
FY, 2023
Gritstone bio Summary
Company Summary
- Overview
- Gritstone bio is a company that develops vaccines for cancers and infectious diseases. It leverages the EDGE (Epitope Discovery for GEnomes) and other AI platforms to research T cells and immune responses for the development of immunotherapy drugs.
- Type
- Public
- Status
- Active
- Founded
- 2015
- HQ
- Emeryville, CA, US | view all locations
- Website
- https://gritstonebio.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Celia Economides, Executive Vice President and Chief Financial Officer
Matthew Hawryluk, Executive Vice President and Chief Business Officer
Erin E. Jones, Executive Vice President and Chief Operating Officer
LocationsView all
6 locations detected
Emeryville, CA HQ
United States
5959 Horton St #300
NY
United States
6201 15th Ave, Brooklyn
Cambridge, MA
United States
40 Erie St #120
Menlo Park, CA
United States
140 Scott Dr
Pleasanton, CA
United States
4698 Willow Rd
Redwood City, CA
United States
275 Shoreline Dr #600
Gritstone bio Financials
Summary Financials
- Revenue (Q2, 2024)
- $921.0K
- Net income (Q2, 2024)
- ($23.4M)
- Cash (Q2, 2024)
- $50.9M
- EBIT (Q2, 2024)
- ($27.6M)
- Enterprise value
- $568.1K